Advertisement

Advancing cellular therapies towards standard of care: a focus on testing of cellular therapy products

  • PATRICK J. Hanley
    Correspondence
    Correspondence: Patrick J. Hanley, PhD, Center for Cancer and Immunology Research, Center for Cancer and Blood Disorders, Children's Research Institute,Children's National Medical Center and The George Washington University, 111 Michigan Ave NW, Washington, DC 20010, USA.
    Affiliations
    Center for Cancer and Immunology Research, Center for Cancer and Blood Disorders, Children's Research Institute, Children's National Medical Center and The George Washington University, Washington, DC, USA

    Centre for Cell, Gene & Tissue Therapeutics, Royal Free Hospital, London, UK
    Search for articles by this author
  • MARK Lowdell
    Affiliations
    Immuno-Gene Therapy Scientific Committee, International Society for Cell and Gene Therapy, Vancouver, Canada

    Department of Haematology, Cancer Institute, University College London, London, UK

    Centre for Cell, Gene & Tissue Therapeutics, Royal Free Hospital, London, UK
    Search for articles by this author
Published:March 07, 2019DOI:https://doi.org/10.1016/j.jcyt.2019.02.003
      The field of cell and gene therapy has rapidly grown from a number of small, isolated centers 20years ago to specialized cell and gene therapy centers worldwide. Nonetheless, despite the recent high-profile acquisitions of small companies developing cell therapies such as chimeric antigen receptor (CAR)-T products, the bulk of developments in this field remain led by academic drug developers, most of whom are focused on a treatment for their group of patients with local production and supply and are not aware of the challenges of supplying the national or global patient need.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect